Patent application number | Description | Published |
20080242619 | Growth hormone releasing peptides - Disclosed are peptide and peptidomimetic compounds generally according to formula (I), and pharmaceutically acceptable salts thereof, that are useful as GHRP analogs: R | 10-02-2008 |
20090131478 | Growth Hormone Secretagogues - A family of peptides and peptidomimetic compounds useful as GHS analogs according to either formula (I) or (II) as depicted below: or a pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification. | 05-21-2009 |
20090149378 | GLP-1 ANALOGUES - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. | 06-11-2009 |
20090156483 | Analogs of Ghrelin - The invention comprises peptidyl analogs according to formulae (I) or (II) as depicted below: | 06-18-2009 |
20090163416 | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment - A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib | 06-25-2009 |
20090197802 | Analogues of GLP-1 - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. | 08-06-2009 |
20090232838 | Ligands of melanocortin receptors - The present invention is directed to a compound according to formula, (R | 09-17-2009 |
20090275501 | Somatostatin-dopamine chimeric analogs - Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is:
| 11-05-2009 |
20090275511 | ANALOGS OF GHRELIN SUBSTITUTED AT THE N-TERMINAL - The invention comprises peptidyl analogs of ghrelin having greater stability which are active at the GHS receptor according to formulae depicted below: | 11-05-2009 |
20090304724 | Compositions and Methods for Stimulating Gastrointestinal Motility - The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient. | 12-10-2009 |
20100016550 | Methods for Site-Specific Pegylation - The present invention relates to methods for the chemo-selective pegylation of the cysteine residue having unoxidized sulfhydryl side-chain and free α-amino group in proteins, peptides and other molecules. Similar methods are provided for the chemo-selective pegylation of the homocysteine, selenocysteine, penicillamine, and N-methyl-cysteine residues. | 01-21-2010 |
20100069299 | Ghrelin analogs - The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof. | 03-18-2010 |
20100087365 | Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof - The present invention is directed to pharmaceutical composition comprising a clear solution or an aqueous mixture, a suspension or a semisolid of at least one peptide compound selected from the group consisting of hGLP-1(7-36)-NH | 04-08-2010 |
20100113367 | PEPTIDE-CYTOTOXIC CONJUGATES - The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions. | 05-06-2010 |
20100137204 | GLP-1 PHARMACEUTICAL COMPOSITIONS - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues. | 06-03-2010 |
20100173834 | CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, (R | 07-08-2010 |
20100179304 | Somatostatin-Dopamine Chimeric analogs - Disclosed is a series of somatostatin-dopamine chimeric analogs which retain both somatostatin and dopamine activity in vivo. An example is: 6-n-propyl-8β-ergolinglmethylthioacetyl-D-Phe-c(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH | 07-15-2010 |
20100184646 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction. | 07-22-2010 |
20100204449 | METHODS AND INTERMEDIATES FOR CHEMICAL SYNTHESIS OF POLYPEPTIDES AND PROTEINS - The present invention relates to methods and intermediates for chemical synthesis of polypeptides and proteins, and more particularly to methods and intermediates for chemically ligating a peptide fragment containing N-terminal β-methyl-cysteine (SEQ ID NO: 1) with another peptide fragment having C-terminal thioester to generate a β-amino-thioester intermediate that spontaneously rearranges to form an amide bond. The invention also relates to methods of synthesizing β-methyl-cysteine (SEQ ID NO: 1) and its protected forms. Furthermore, the invention relates to converting a β-methyl-thiazolidine residue to a β-methyl-cysteine (SEQ ID NO: 1) residue of polypeptides and proteins. | 08-12-2010 |
20100234564 | METHODS AND INTERMEDIATES FOR CHEMICAL SYNTHESIS OF POLYPEPTIDES AND PROTEINS - The present invention relates to methods and intermediates for chemical synthesis of polypeptides and proteins, and more particularly to methods and intermediates for chemically ligating a peptide fragment containing N-terminal N-methyl-cysteine (SEQ ID NO: 1) with another peptide fragment having C-terminal thioester to generate a β-(methylamino)-thioester intermediate that spontaneously rearranges to form an amide bond. Furthermore, the invention relates to methods of converting N-methyl-thiazolidine to N-methyl-cysteine (SEQ ID NO: 1) of polypeptides and proteins. The invention also relates to methods of synthesizing peptide-thioester from peptide-acid fluoride. | 09-16-2010 |
20100279922 | Melanocortin Receptor Ligands - The present invention is directed to compounds according to formula, | 11-04-2010 |
20100331245 | PEPTIDE YY ANALOGS - The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion. | 12-30-2010 |
20110038885 | CHEMOKINE ANALOGS - The present invention is directed to peptide analogs of chemokine, the pharmaceutically acceptable salts thereof, to methods of using such analogs to treat mammals and to pharmaceutical compositions useful therefor comprising said analogs. | 02-17-2011 |
20110065632 | PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN-DOPAMINE CONJUGATES - The present invention is directed to improvements in compositions containing a somatostatin-dopamine conjugate which retains both somatostatin and dopamine activity in vivo, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH | 03-17-2011 |
20110136724 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 06-09-2011 |
20110136725 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) MODIFIED AT N-TERMINAL - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 06-09-2011 |
20110136733 | ANALOGUES OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 06-09-2011 |
20110144007 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE ANALOGUES - There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity. | 06-16-2011 |
20110160133 | METHOD FOR INHIBITING INFLAMMATION AND PRE-INFLAMMATORY CYTOKINE/CHEMOKINE EXPRESSION USING A GHRELIN ANALOGUE - The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin. | 06-30-2011 |
20110166069 | COMPOSITIONS AND METHODS FOR STIMULATING GASTROINTESTINAL MOTILITY - The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient. | 07-07-2011 |
20110183886 | MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, | 07-28-2011 |
20120010154 | Cytotoxic Conjugates Having Neuropeptide Y Receptor Binding Compound - There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors. | 01-12-2012 |
20120040885 | Analogues of Neuropeptide Y Having At Least One Synthetic Amino Acid Substitution - The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype. | 02-16-2012 |
20120040886 | Analogues of Neuropeptide Y Having Proline Substitution At Position 34 - The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype. | 02-16-2012 |
20120129767 | USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT - A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib | 05-24-2012 |
20120190616 | Analogues of Insulin-Like Growth Factor-1 (IGF-1) Having Amino Acid Substitution at Position 59 - The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn | 07-26-2012 |
20120225816 | Pharmaceutical Compositions of Melanocortin Receptor Ligands - The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH | 09-06-2012 |
20120226018 | Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 - The present invention relates to a novel process for the synthesis of the melanocortin analog, Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH | 09-06-2012 |
20120277151 | GLP-1 PHARMACEUTICAL COMPOSITIONS - The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefore comprising said analogues. | 11-01-2012 |
20130030148 | PROCESS FOR THE SYNTHESIS OF (AIB8,35)HGLP-1(7-36)-NH2 - The present invention relates to a process for the large-scale synthesis of (Aib | 01-31-2013 |
20130123170 | Growth Hormone Releasing Peptides - Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: | 05-16-2013 |
20130210751 | Pharmaceutical Compositions of Growth Hormone Secretagogue Receptor Ligands - The present invention relates to improvements in compositions containing peptides that are ligands of the GHS receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, which is a ligand of the GHS receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of lower than 1000. | 08-15-2013 |
20140121354 | Somatostatin-Dopamine Chimeric Analogs - The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions. | 05-01-2014 |
20140135260 | Ghrelin Analogs - The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof. | 05-15-2014 |
20150031615 | Growth Hormone Releasing Peptides - Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: | 01-29-2015 |